Company news

Seres Therapeutics, Inc. news

Latest news releases, newest first. Pick a year for every news release, call and deck from that year.

View company

Seres Therapeutics Announces VOWST™ Commercial Launch Update and US FDA Fast Track Designation for SER-155

January 8, 2024

Seres Therapeutics Announces Presentation of Preliminary PK/PD and Safety Data for Investigational Microbiome Therapeutic SER-155 at ASH 2023

December 6, 2023

Seres Therapeutics Reports Third Quarter 2023 Financial Results Including VOWST™ Net Sales of $7.6 Million

November 1, 2023

Seres Therapeutics to Announce Third Quarter 2023 Results on Thursday, November 2, 2023; Host Conference Call and Webcast at 8: 00 a.m. EST

October 29, 2023

Seres Therapeutics Reports Second Quarter 2023 Financial Results and Provides Business Updates

August 7, 2023

Seres Therapeutics and Nestlé Health Science Announce U.S. Commercial Availability of VOWST™, the First and Only FDA-Approved Microbiota-Based Oral Therapeutic for Prevention of Recurrence of C. Difficile Infection

June 4, 2023

Seres Therapeutics Announces Receipt of $125 Million Milestone From Nestlé Health Science Following FDA Approval of VOWST™

May 29, 2023

Seres Therapeutics Reports SER-155 Phase 1b Cohort 1 Results Showing Successful Drug Bacteria Engraftment and Substantial Reduction in Pathogen Domination in the Gastrointestinal Microbiome

May 8, 2023

Seres Therapeutics Reports First Quarter 2023 Financial Results and Provides Business Updates

May 8, 2023

Seres Therapeutics and Nestlé Health Science Present Results from ECOSPOR IV Phase 3 Study of VOWST™, a Microbiota-Based Oral Therapeutic for Prevention of Recurrence of C. Difficile Infection, at the Digestive Disease Week (DDW) Annual Meeting

May 7, 2023

Seres Therapeutics Announces $250 Million Debt Financing with Oaktree

April 26, 2023

Seres Therapeutics and Nestlé Health Science Announce FDA Approval of VOWSTTM (fecal microbiota spores, live-brpk) for Prevention of Recurrence of C. difficile Infection in Adults Following Antibacterial Treatment for Recurrent CDI

April 25, 2023

Seres Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Updates

March 6, 2023

Seres Therapeutics Announces Initiation of Enrollment in SER-155 Phase 1b Study Cohort 2 in Individuals Undergoing Allogeneic Hematopoietic Stem Cell Transplantation

February 7, 2023

Seres Therapeutics Appoints Genomic Medicine and Microbiology Pioneer Claire M. Fraser, Ph.D., to its Board of Directors and Announces SER-155 Phase 1b Study Progress

January 4, 2023

Seres Therapeutics Reports Third Quarter 2022 Financial Results and Provides Business Updates

November 1, 2022

Seres Therapeutics Announces FDA Acceptance of Biologics License Application for Investigational Microbiome Therapeutic SER-109 for Recurrent C. Difficile Infection for Priority Review

October 25, 2022

Seres Therapeutics Announces Completion of Rolling BLA Submission to FDA for Investigational Microbiome Therapeutic SER-109 for Recurrent C. Difficile Infection

September 6, 2022

Seres Therapeutics Reports Second Quarter 2022 Financial Results and Provides Business Updates

August 2, 2022

Seres Therapeutics Announces $100 Million Registered Direct Offering of Common Stock

June 29, 2022

Seres Therapeutics Announces Confirmatory Results from Investigational Microbiome Therapeutic SER-109 ECOSPOR IV Open-Label Study in Recurrent C. Difficile Infection

June 6, 2022

Seres Therapeutics Presents Phase Ill Results of SER-109 for Recurrent C. Difficile Infection at the Digestive Disease Week (DDW) Annual Meeting

May 21, 2022

Seres Therapeutics Reports First Quarter 2022 Financial Results and Provides Business Updates

May 3, 2022

Seres Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Business Updates

February 28, 2022

Seres Therapeutics Appoints Paula Cloghessy as Executive Vice President, Chief People Officer

February 7, 2022

Seres Announces Preliminary SER-287 Phase 2b ECO-RESET Study Microbiome Data Analysis

December 15, 2021

Seres Therapeutics Announces First Patient Enrolled in Phase 1b Study of SER-155, an Investigational Microbiome Therapeutic to Reduce the Risk of Antibiotic-Resistant Bacterial Infections and Graft-Versus-Host Disease (GvHD)

November 29, 2021

Seres Therapeutics Reports Third Quarter 2021 Financial Results and Provides Business Updates

November 9, 2021

Bacthera and Seres Therapeutics Collaborate for Commercial Manufacturing of SER-109, a Potential Treatment Against Recurrent C. difficile Infection

November 9, 2021

Seres Therapeutics Presents Late-Breaking Data from SER-109 Phase 3 ECOSPOR III Study in Recurrent C. Difficile Infection at IDWeek2021

October 1, 2021

Seres Therapeutics Achieves Enrollment of 300 Subjects with Phase 3 ECOSPOR IV Open-Label Extension Study of SER-109, a Potentially First-in-Class Investigational Microbiome Therapeutic for Recurrent C. difficile Infection

September 14, 2021

Seres Therapeutics Reports Second Quarter 2021 Financial Results and Provides Business Updates

August 2, 2021

Seres Therapeutics Announces Topline Results for SER-287 Phase 2b Study in Mild-to-Moderate Ulcerative Colitis

July 21, 2021

Seres Therapeutics, Nestlé Health Science Announce SER-109 Co-Commercialization License Agreement

June 30, 2021

Seres Therapeutics to Host Virtual Investor Event on June 21, 2021

June 9, 2021

Seres Therapeutics Announces FDA Clearance of IND for SER-155, an Investigational Microbiome Therapeutic for the Prevention of Antibiotic-Resistant Bacterial Infections and Graft-versus-Host Disease (GvHD)

May 31, 2021

Seres Therapeutics Announces David Arkowitz to Join as Executive Vice President, Chief Financial Officer and Head of Business Development

May 19, 2021

Seres Therapeutics Reports First Quarter 2021 Financial Results and Provides Business Updates

May 3, 2021

Seres Therapeutics Announces Discontinuation of Enrollment in SER-401 Study in Metastatic Melanoma

March 7, 2021

Seres Therapeutics Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Business Updates

March 1, 2021

Seres Therapeutics Announces Achievement of Target Enrollment in SER-287 Phase 2b ECO-RESET Study for Ulcerative Colitis

March 1, 2021

Seres Therapeutics Reports Third Quarter 2020 Financial Results and Provides Business Updates

November 8, 2020

Seres Therapeutics Announces Initiation of Phase 1b Trial of SER-301 for the Treatment of Ulcerative Colitis

November 5, 2020

Seres Therapeutics Expands Executive Team with Appointments of David S. Ege, Ph.D., as Chief Technology Officer and Jayne M. Gansler as Chief People Officer

October 21, 2020

Seres Therapeutics Announces U.S. Food and Drug Administration Correspondence Following Positive SER-109 Phase 3 Study Results

September 10, 2020

Seres Therapeutics, Inc. Announces Closing of Public Offerings of 12,075,000 Shares of Common Stock

August 16, 2020

Seres Therapeutics, Inc. Announces Pricing of Public Offering of 10,500,000 Shares of Common Stock

August 11, 2020

Seres Therapeutics, Inc. Announces Proposed Public Offering of Common Stock

August 10, 2020

Seres Therapeutics Announces Positive Topline Results from SER-109 Phase 3 ECOSPOR III Study in Recurrent C. difficile Infection

August 9, 2020

Seres Therapeutics Reports Second Quarter 2020 Financial Results and Provides Business Updates

July 27, 2020

← Newer news releases · Older news releases →

Calls

The 5 newest of 20 calls. Every call is listed under its year.

Decks

The 5 newest of 54 decks. Every deck is listed under its year.